Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

NCT05586230 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

NIH

Sponsor class

Conditions

Tuberculosis
Rifampicin Resistant Tuberculosis

Interventions

DRUG: Pretomanid
DRUG: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]